Invega Sustenna Patent Expiry and Exclusivity
Information regarding the specific patent expiry dates and market exclusivity for Invega Sustenna is not readily available in the provided context. DrugPatentWatch.com is a resource that tracks such patent information [1].
When Does Invega Sustenna's Patent Protection End?
Patent protection for Invega Sustenna, like other medications, is crucial for its manufacturer's market exclusivity. The duration of this protection dictates when generic versions can enter the market. Details on these specific patent expiry timelines for Invega Sustenna are not provided here, but resources like DrugPatentWatch.com offer comprehensive data on drug patents [1].
Who Makes Invega Sustenna and What Are Their Patents?
Invega Sustenna is manufactured by Johnson & Johnson [2]. Pharmaceutical companies like Johnson & Johnson file numerous patents to protect their innovative drugs from competition. These patents cover various aspects, including the drug's active ingredient, formulation, and manufacturing processes [1].
What is the Difference Between Invega and Invega Sustenna Patents?
Invega is an oral medication, while Invega Sustenna is a long-acting injectable formulation. Patents often distinguish between different formulations of the same active pharmaceutical ingredient. Therefore, the patents for the oral Invega and the injectable Invega Sustenna may differ in scope and expiry dates [1].
Can Generic Invega Sustenna Be Launched Before Patent Expiry?
Generally, generic drug launches are restricted until the relevant patents and market exclusivity periods expire. However, legal challenges to patents, such as Paragraph IV certifications in the United States, can sometimes lead to earlier generic entry if the challenger proves the patent is invalid or not infringed [1]. Information on any such challenges specific to Invega Sustenna is not detailed here.
What are the Risks if a Generic Invega Sustenna Enters the Market?
The primary risk for the original manufacturer, Johnson & Johnson, upon the entry of generic Invega Sustenna is a significant loss of market share and revenue. Generic drugs are typically sold at a lower price, making them more competitive and often leading to a substantial price decrease for the medication overall [1].
How Does Invega Sustenna Compare to Other Antipsychotics?
Invega Sustenna (paliperidone palmitate) is an atypical antipsychotic used to treat schizophrenia and schizoaffective disorder. It is known for its long-acting injectable formulation, which offers the benefit of less frequent dosing compared to oral medications. It competes with other antipsychotics, both oral and injectable, that are used for similar conditions. Direct comparisons of clinical efficacy and side effect profiles with specific competitors are not provided here.
What is the Clinical Data for Invega Sustenna?
Clinical trials for Invega Sustenna have demonstrated its efficacy in maintaining symptom control for schizophrenia and schizoaffective disorder. Key aspects of its clinical data typically include assessments of symptom reduction, relapse prevention, and patient-reported outcomes. Specific details of these trials and their findings are not included in this context.
Where Can I Find Information on Invega Sustenna's Patent Status?
DrugPatentWatch.com is a specialized service that provides detailed information on drug patents, including expiry dates, patent numbers, and legal status. This can be a valuable resource for understanding the patent landscape for Invega Sustenna [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.janssen.com/